Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new trial starting in January 2016 will compare different medical devices used in hip fracture surgery, aiming to improve the efficiency of these operations.

Xavier Griffin, Consultant Trauma Surgeon, Oxford University Hospitals Foundation Trust and Chief Investigator on the trial says: "Fractures of the hip are the most devastating of the musculoskeletal fragility injuries that we see in orthopaedic trauma practice in the UK. They alone make up 1.4% of health and social care costs and herald a step change in patients mobility and independence.

Interventions which can help us better treat these injuries are crucial to improving the health of our patients. We are excited about our new collaboration with X-Bolt Orthopaedics which will allow us to investigate this implant for fixation of hip fractures which may yield better outcomes for these patients."

Fractures of the hip are the most devastating of the musculoskeletal fragility injuries that we see in orthopaedic trauma practice in the UK - Xavier Griffin, Consultant Trauma Surgeon and Chief Investigator

Hip fractures account for an estimated £1.1 billion in hospital costs annually, with failed hip fracture fixations and re-operations accounting for approximately £30m; the impact on the patients and loss of independence are immeasurable.

The 1000 patient, multicentre, randomised, controlled trial World Hip Trauma Evaluation Four (WHiTE Four) will compare two different treatments for extracapsular hip fractures - sliding hip screw fixation (SHS) and X-Bolt Dynamic Hip Plating system - following a successful smaller clinical trial that showed a zero re-operation risk for the X-Bolt System.

SHS is well established in the treatment of extracapsular fractures. However, in some hip fractures there is deficient bone to share load with the fixation device leading to failure of the fixation, often leading to more surgery and poor outcomes.

The new X-Bolt Dynamic Hip plating system builds on the successful design features of the SHS but differs in the nature of the fixation in the head. The system was designed to significantly improve the effectiveness of current surgical treatment and reduce the requirement for very costly and often devastating repeat surgery.

Both operations carry substantial and similar general risks due to the nature of the surgery and the typical frailty of the patient population. Treatment of this type of fracture remains controversial but the potential advantages of improved fixation in the femoral head may reduce failure rates with this novel device compared to the current gold standard.

WHITE-4_logo

Similar stories

NDORMS joins research partnership to understand links between overlapping long-term conditions

The links between different long-term health conditions will be explored in new research funded with a £2.5million grant from the Medical Research Council.

NDORMS researchers awarded grant for study on the effects of COVID-19 vaccines on long COVID

A team of NDORMS researchers including Doctor Annika Jödicke and Doctor Victoria Strauss have been awarded NIHR funding to carry out a study into the effects of different COVID-19 vaccines on long COVID.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Researchers show the role of cilia in cartilage health

New research shows that disrupting primary cilia in juvenile, adolescent and early adulthood in cartilage stops it maturing correctly, making it more prone to thinning and the potential for osteoarthritis (OA) in later life.

New research could improve quality of life for Psoriatic Arthritis patients

Professors Laura Coates and Dani Prieto-Alhambra will take major roles in a new European Commission project to develop innovative personalised treatment options for people affected by psoriatic arthritis.